Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells 1,697 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. This represents a 0.97 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Halozyme Therapeutics Stock Performance

NASDAQ HALO traded down $1.45 during trading on Monday, reaching $57.70. 755,004 shares of the company's stock were exchanged, compared to its average volume of 1,276,205. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The business has a 50 day moving average price of $54.53 and a 200-day moving average price of $54.72. The stock has a market capitalization of $7.11 billion, a P/E ratio of 16.87, a PEG ratio of 0.42 and a beta of 1.25. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.73 and a fifty-two week high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Remove Ads

Institutional Trading of Halozyme Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Venturi Wealth Management LLC bought a new position in Halozyme Therapeutics in the 4th quarter valued at about $69,000. RPg Family Wealth Advisory LLC acquired a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $1,886,000. Segall Bryant & Hamill LLC increased its stake in shares of Halozyme Therapeutics by 16.3% during the third quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company's stock worth $20,330,000 after purchasing an additional 49,856 shares during the period. Retirement Systems of Alabama lifted its holdings in Halozyme Therapeutics by 23.5% during the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company's stock worth $22,282,000 after purchasing an additional 74,173 shares during the last quarter. Finally, South Street Advisors LLC bought a new stake in Halozyme Therapeutics in the 3rd quarter valued at $9,812,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Benchmark reiterated a "buy" rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Piper Sandler boosted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research report on Friday, January 10th. Wells Fargo & Company decreased their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Finally, HC Wainwright upped their target price on Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a "buy" rating in a report on Wednesday, February 19th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.